Literature DB >> 33625551

Freiburg Neuropathology Case Conference : Contrast-enhancing Brain Lesion 6 Months after Resection and Combined Radiotherapy and Chemotherapy of an Unmethylated but IDH R132H-mutated Glioblastoma Multiforme.

T Demerath1, D Erny2, O Schnell3, H Urbach1, M Prinz2, C A Taschner4.   

Abstract

Entities:  

Keywords:  Cerebral abscess; Cerebritis; Pseudoprogression; Radionecrosis; Tumor progression

Year:  2021        PMID： 33625551      PMCID： PMC7943525          DOI： 10.1007/s00062-021-01006-4

Source DB:  PubMed          Journal:  Clin Neuroradiol        ISSN： 1869-1439            Impact factor:   3.649


× No keyword cloud information.
  15 in total

1.  Differentiation of true progression from pseudoprogression in glioblastoma treated with radiation therapy and concomitant temozolomide: comparison study of standard and high-b-value diffusion-weighted imaging.

Authors:  Hee Ho Chu; Seung Hong Choi; Inseon Ryoo; Soo Chin Kim; Jeong A Yeom; Hwaseon Shin; Seung Chai Jung; A Leum Lee; Tae Jin Yoon; Tae Min Kim; Se-Hoon Lee; Chul-Kee Park; Ji-Hoon Kim; Chul-Ho Sohn; Sung-Hye Park; Il Han Kim
Journal:  Radiology       Date:  2013-10-28       Impact factor: 11.105

2.  Diagnosis of pseudoprogression using MRI perfusion in patients with glioblastoma multiforme may predict improved survival.

Authors:  Seymur Gahramanov; Csanad Varallyay; Rose Marie Tyson; Cynthia Lacy; Rongwei Fu; Joao Prola Netto; Morad Nasseri; Tricia White; Randy L Woltjer; Sakir Humayun Gultekin; Edward A Neuwelt
Journal:  CNS Oncol       Date:  2014-11

3.  Differentiation of pyogenic brain abscesses from necrotic glioblastomas with use of susceptibility-weighted imaging.

Authors:  C H Toh; K-C Wei; C-N Chang; P-W Hsu; H-F Wong; S-H Ng; M Castillo; C-P Lin
Journal:  AJNR Am J Neuroradiol       Date:  2012-03-15       Impact factor: 3.825

Review 4.  Pseudoprogression and hyperprogression after checkpoint blockade.

Authors:  Qiaohong Wang; Jingze Gao; Xia Wu
Journal:  Int Immunopharmacol       Date:  2018-03-23       Impact factor: 4.932

Review 5.  Pseudoprogression, radionecrosis, inflammation or true tumor progression? challenges associated with glioblastoma response assessment in an evolving therapeutic landscape.

Authors:  Benjamin M Ellingson; Caroline Chung; Whitney B Pope; Jerrold L Boxerman; Timothy J Kaufmann
Journal:  J Neurooncol       Date:  2017-04-05       Impact factor: 4.130

6.  Morphologic magnetic resonance imaging features of therapy-induced cerebral necrosis.

Authors:  L R Rogers; J Gutierrez; L Scarpace; L Schultz; S Ryu; B Lord; B Movsas; J Honsowetz; R Jain
Journal:  J Neurooncol       Date:  2010-05-20       Impact factor: 4.130

7.  Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.

Authors:  Roger Stupp; Warren P Mason; Martin J van den Bent; Michael Weller; Barbara Fisher; Martin J B Taphoorn; Karl Belanger; Alba A Brandes; Christine Marosi; Ulrich Bogdahn; Jürgen Curschmann; Robert C Janzer; Samuel K Ludwin; Thierry Gorlia; Anouk Allgeier; Denis Lacombe; J Gregory Cairncross; Elizabeth Eisenhauer; René O Mirimanoff
Journal:  N Engl J Med       Date:  2005-03-10       Impact factor: 91.245

Review 8.  Imaging of cerebritis, encephalitis, and brain abscess.

Authors:  Tanya J Rath; Marion Hughes; Mohammad Arabi; Gaurang V Shah
Journal:  Neuroimaging Clin N Am       Date:  2012-09-28       Impact factor: 2.264

Review 9.  Imaging Glioblastoma Posttreatment: Progression, Pseudoprogression, Pseudoresponse, Radiation Necrosis.

Authors:  Sara B Strauss; Alicia Meng; Edward J Ebani; Gloria C Chiang
Journal:  Radiol Clin North Am       Date:  2019-08-16       Impact factor: 2.303

10.  Differentiation of progressive disease from pseudoprogression using 3D PCASL and DSC perfusion MRI in patients with glioblastoma.

Authors:  Paul Manning; Shadi Daghighi; Matthew K Rajaratnam; Sowmya Parthiban; Naeim Bahrami; Anders M Dale; Divya Bolar; David E Piccioni; Carrie R McDonald; Nikdokht Farid
Journal:  J Neurooncol       Date:  2020-04-01       Impact factor: 4.130
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.